The expression of multiple cardiac troponin T (cTnT) isoforms has been demonstrated in diseased human skeletal muscle. However, cardiac troponin I (cTnI) expression has been described only in heart muscle. The goal of this study was to determine whether mRNA for cTnT, slow skeletal troponin T (sTnT), or cTnI was expressed in skeletal muscle biopsies obtained from patients with end-stage renal disease (ESRD) and Duchenne muscular dystrophy (DMD). Methods: Total mRNA was extracted from healthy human heart (n ‫؍‬ 4), healthy human skeletal muscle (n ‫؍‬ 5), and skeletal muscle from patients with ESRD (n ‫؍‬ 7) and DMD (n ‫؍‬ 5). Total RNA (1 g) was reversetranscribed using Moloney murine leukemia virus reverse transcriptase. The reverse-transcribed cDNAs were amplified by PCR using oligonucleotide primers specific for cTnT, sTnT, and cTnI sequences (GenBank accession numbers X74819, m19308, and X54163, respectively). Results: In all heart specimens, a 150-bp cTnT amplicon was detected. Skeletal muscle from four of seven patients with ESRD and two of five patients with DMD showed expression of a 150-bp amplicon. Using DNA sequencing and a comparison program, the 150-bp amplicons found in heart and diseased skeletal muscle specimens were 100% identical and specific to the cTnT mRNA sequence. No cTnT mRNA expression was found in healthy skeletal muscle. No evidence of sTnT mRNA was found in heart muscle. A 200-bp sTnT amplicon specific to a human sTnT sequence was detected in all skeletal muscle specimens. A 250-bp cTnI amplicon specific to the cTnI sequence was detected in all heart specimens. However, no cTnI mRNA expression was found in healthy or diseased skeletal muscle
Cardiac troponin T (cTnT) 1 and cardiac troponin I (cTnI) have unique amino acid sequences that differentiate them from their respective skeletal muscle isoforms, allowing for the development of isoform-specific monoclonal antibodies (MAbs) (1, 2 ) . Four isoforms of cTnT are expressed in developing cardiac muscle through combinatorial alternative splicing of two 5Ј exons in a developmentally regulated manner (3 ) . cTnT isoforms have also been described in fetal human skeletal muscle, where there is a developmental down-regulation of cTnT and up-regulation of skeletal isoforms of TnT, leading to the absence of cTnT in healthy adult skeletal muscle (4, 5 ) . In contrast, healthy human cardiac muscle contains a single cTnI, which is not detected in healthy adult skeletal muscle. Furthermore, skeletal muscle does not express cTnI at any point during development.
Studies using immunochemical staining analysis and Western blot analysis have demonstrated that several cTnT isoforms are re-expressed during regeneration in adult rat skeletal muscle after injury or denervation (6 ) and in human skeletal muscle from patients with Duchenne muscular dystrophy (DMD) (7 ) , polymyositis (7 ) , and end-stage renal disease (ESRD) (8 ) . The mechanism for expression of cTnT isoforms in skeletal muscle from ESRD patients is likely associated with peripheral myopathy associated with renal disease (9 ) . Expression of cTnT isoforms in diseased or regenerating skeletal muscle appears to represent re-expression of the cTnT gene, given that fetal skeletal muscle expresses cTnT (6 ) .
The presence of circulating cTnT and cTnI in blood is a specific indicator of heart muscle damage. This observation serves as the basis for using cTnT and cTnI measurement to diagnose acute myocardial infarction (10, 11 ) . Furthermore, the observations that cTnT and cTnI can be released during unstable angina led to the recognition of small amounts of myocardial damage (12) (13) (14) . The incidence and prognostic value of increased cTnT and cTnI concentrations in chronic hemodialysis patients, independent of their history of coronary artery disease, has not been fully characterized. In a previous study, however, we carefully characterized cTnT isoform expression in skeletal muscle from patients with ESRD using the two MAbs from the second-and third-generation Roche cTnT immunoassays and demonstrated that measurable cTnT in the circulation is cardiac specific (15 ) .
The purpose of the current study was to determine mRNA and protein expression of cTnT and cTnI in diseased and healthy human skeletal muscle.
Materials and Methods subjects
Skeletal muscle biopsies were obtained from seven ESRD hemodialysis patients (abdominal wall, back muscles, and arm muscles) and five DMD patients (arm muscles). All ESRD patients had predialysis creatinine concentrations Ͼ50 mg/L. Human heart (n ϭ 5) and skeletal muscle (n ϭ 5) specimens were obtained at autopsy within 24 h of death from three subjects who expired after non-cardiacrelated and non-myopathy-related illnesses. Informed consent was obtained according to the Institutional Human Subjects Research Review Board guidelines. The biopsied tissues were frozen in liquid nitrogen and stored at Ϫ70°C until analysis. rna isolation from patient muscles RNA was extracted from all heart and skeletal muscle tissues. Fifty to 100 mg of each tissue was homogenized with a Polytron homogenizer (Brinkman Instruments), using a commercial procedure modified from the guanidine-isothiocyanate-phenol method developed by Chomczynski and Sacchi (16 ) . The cell components were disrupted in 1 mL of TRIzol reagent (Life Technologies TM ), and homogenates were incubated at room temperature for 30 min. After the addition of 0.2 mL of chloroform per 1 mL of homogenate, tubes were mixed by vortex-mixing for 5 s and incubated at room temperature for 5 min. Samples were centrifuged at 12 000g for 15 min at 4°C. RNA was recovered from the upper aqueous phase (600 L) by precipitation with 0.5 mL of isopropyl alcohol. Samples were incubated at room temperature for 15 min and centrifuged at 12 000g for 15 min at 4°C. The supernatants were removed, and the RNA pellets were washed twice with 1 mL of 750 mL/L ethanol. The samples were mixed by vortex-mixing and centrifuged at 7500g for 5 min at 4°C. The RNA pellets were air dried 5 min at room temperature and reconstituted in 20 L of RNase-free water. The purity of the RNA was determined from the ratio of absorbance readings at 260 and 280 nm, with an A 260/280 ratio between 1.8 and 2.0 indicating sufficient purity. The concentration of RNA was determined from the absorbance at 260 nm. RNA samples were kept frozen at Ϫ75°C until used.
reverse transcription-pcr (rt-pcr) of troponin in skeletal muscle
One microgram of total RNA was reverse-transcribed using Moloney murine leukemia virus reverse transcriptase (SuperScript TM II; Life Technologies) according to the supplier's protocol. Forward and reverse primers were designed using the primer design and analysis software Oligo 6.01 (Molecular Biology Insights). The reversetranscribed cDNAs were amplified by PCR using the following oligonucleotide primers: Samples were mixed gently, and 2 drops of silicon oil (Sigma) were layered over the reaction solution. The reaction tubes were heated at 94°C for 3 min for denaturation, followed by 40 cycles of PCR at 94°C for 10 s and 68°C for 45 s in a DNA thermal Cycler (GenAmp PCR System 2400; Perkin-Elmer). The amplified DNA fragments were visualized by 4% modified agarose gel (NuSieve ® ; FMC BioProducts) electrophoresis combined with ethidium bromide staining. Two micrograms of 100-bp DNA ladder (100 -2000 bp; Life Technologies) was used as a reference control to estimate the PCR amplicon length. The amplicons obtained by RT-PCR from heart and skeletal muscle mRNAs were compared using DNA sequencing (University of Maine System, Orono, ME) and a sequence comparison software program (Genetic Computer Group, Ver. 9.1).
protein extraction
As described previously (15 ) , all samples (ϳ50 mg) of frozen nondiseased human heart muscle (n ϭ 5), nondiseased human skeletal muscle (n ϭ 5), and diseased skeletal muscle from patients with ESRD (n ϭ 7) or DMD (n ϭ 5) were coarsely ground in a liquid nitrogen-cooled mortar and then added to a protein extraction buffer (200 mmol/L potassium phosphate, pH 7.4, 5.0 mmol/L EGTA, 5.0 mmol/L ␤-mercaptoethanol, and 100 mL/L glycerol). The samples were homogenized at 4°C. The supernatants were used immediately for protein analysis and Western blotting.
antibodies Three different primary MAbs were selected for use in Western blotting, as described previously (15 ) . A mouse MAb specific for cTnI (JS-1; specific residues recognized on cTnI protein sequence not available from manufacturer) was a gift from Lakeland Biomedical, Minneapolis, MN, and was used at 2 mg/L (7 ). Two MAbs specific for cTnT were used (both at a 2 mg/L). MAbs M7 and M11.7, which recognize residues 125-131 and 136 -147, respectively, of the cTnT protein sequence, were provided by Dr. Klaus Hallermayer, Roche Diagnostics, Tutzing, Germany (20 ) . MAbs M11.7 and M7 are the capture and detection antibodies in the Roche cTnT second-and third-generation immunoassays.
western blot analysis
As described previously (15 ) , 50-g samples of all protein extracts were size-fractionated on sodium dodecyl sulfate-polyacrylamide gels using the method of Laemmli (21 ) with the following modifications: 30% acrylamide and 1.1% bis-acrylamide stock solutions were used in 7.5% running gels and 3.3% stacking gels (4 ). Proteins were subsequently transferred to nitrocellulose membrane. After the blocking step, the primary antibody, as described above, was diluted in antibody buffer and incubated with the membrane. The membranes were then washed three times. Appropriate horseradish peroxidaselabeled secondary antibodies (sheep anti-mouse) were then incubated with the membranes for 1 h. The membranes were again washed three times before a 1-min incubation with ECL TM chemiluminescent substrate (Amersham). Light emission was detected by exposure to Fuji RX autoradiography film in the presence of Cronex intensifying screens (Fisher Scientific). Signal intensities within the linear range were quantified by laser densitometry (Molecular Dynamics).
Results
RT-PCR analysis using oligonucleotide primers specific for the cardiac and skeletal muscle isoforms of troponin T and I showed the respective isoform-specific amplification products in both cardiac and skeletal muscle tissue. Fig. 1 shows the RT-PCR amplification of cTnT (Fig. 1A) , cTnI (Fig. 1B) and sTnT (Fig. 1C) cDNA sequences from reverse-transcribed heart and skeletal muscle RNAs. PCR amplification was successful with cardiac muscle-specific primers for cTnT (Fig. 1A) and cTnI (Fig. 1B) when used on heart muscle total RNA (lanes 1-3) . No PCR amplification of cardiac primers in reverse-transcribed RNA was found in healthy skeletal muscle samples (cTnT, lanes 4 -6 in Fig. 1A ; cTnI, lanes 4 -6 in Fig. 1B) . Four of seven skeletal muscle specimens from patients with ESRD (lanes 7, 9, 10, and 12) and two of five skeletal muscle specimens from patients with DMD (lanes 14 and 15) showed amplification at the expected length (150 bp) for cTnT (Fig. 1A) but not for cTnI (Fig. 1B) . We controlled for the presence of intact sTnT mRNA in each biopsy sample tested using primers specific for slow twitch skeletal muscle sequence. No evidence of sTnT mRNA was found in any of the biopsies from healthy hearts (Fig. 1C, lanes  1-3) . However, a 200-bp sTnT amplicon was detected in all biopsies from skeletal muscle specimens (Fig. 1C, lanes  4 -15) .
DNA sequencing analysis for the most representative cTnT amplicons obtained by RT-PCR is shown in Fig. 2 . The comparison analysis of these amplicons with sequences from GenBank database showed that the cTnT 150-bp amplicons found in heart and diseased skeletal muscle specimens were 100% identical and specific to the human cTnT cDNA sequence (GenBank accession number X74819). The cTnI 250-bp amplicons found in heart specimens were 100% identical and specific to the human cTnI cDNA sequence (GenBank accession number X54163; data not shown). The sTnT 200-bp amplicons found in healthy and diseased skeletal muscle specimens were 100% identical and specific to the human slow twitch skeletal TnT cDNA sequence (GenBank accession number m19308; data not shown).
Figs. 3 and 4 show that heart muscle samples demonstrated both mRNA and protein expression for cTnT (250-bp amplicon product and one major 39-kDa isoform and one minor 34-kDa isoform) and for cTnI (150-bp (A), cTnT mRNA; (B), cTnI mRNA; (C), sTnT mRNA. Lanes 1-3, healthy human heart muscle; lanes 4 -6, healthy human skeletal muscle; lanes 7-13, skeletal muscle biopsies from patients with ESRD; lanes 14 and 15, skeletal muscle biopsies from patients with DMD. The 100-bp ladder is shown on the left.
Clinical Chemistry 45, No. 12, 1999 amplicon product and one major 25-kDa isoform). None of the healthy skeletal muscle samples expressed either cTnT or cTnI protein or RNA (Figs. 3 and 4) . However, the four ESRD skeletal muscle samples that demonstrated cTnT isoforms at 34 -36 kDa, as well as the two ESRD muscles that demonstrated a 39-kDa cTnT isoform also showed expression of cTnT RNA by a single amplicon product (Fig. 3) . No expression of either cTnI protein or mRNA was demonstrated in any diseased skeletal muscles (Fig. 4) .
Discussion
This study makes important contributions to the field of RNA expression of human cardiac troponin isoforms in skeletal tissue obtained from ESRD or DMD patients. We demonstrate cTnT isoform expression at the mRNA level in adult human skeletal muscle obtained from patients The 115-bp amplicon sequences showed 100% identity with the cTnT sequence (X74819). Lanes 1, 3, 7, 9, and 10 correspond to the lanes described in the legend of Fig. 1 . Fig. 3 . cTnT protein expression (A and B) and mRNA expression (C) in representative specimens.
Western immunoblots of nondiseased human heart muscle (Heart), nondiseased human skeletal muscle (Normal), and skeletal muscle from ESRD patients (ESRD) were probed with cardiac-specific TnT MAbs M11.7 (A) and M7 (B). (C), PCR amplification of cTnT cDNA from reverse-transcribed muscle mRNA of the same biopsy specimens analyzed by immunoblot. The protein molecular mass markers and 100-bp DNA ladder are shown on the left. with ESRD and DMD, using RT-PCR. To amplify cTnT mRNA in diseased skeletal muscle extracts, the primers (forward and reverse) were designed in a very conserved region within the sequence of adult cTnT isoforms. These cTnT primers were selected from a very specific region (nucleotides 120 -280) of cTnT mRNA when compared with sTnT mRNA sequences. Therefore, comparison analysis of the amplicons with sequences from the GenBank database showed that the 150-bp amplicons found in heart and diseased skeletal muscle specimens were 100% identical and specific to the human cTnT mRNA sequence (Fig. 2) . cTnT primers were designed from the cDNA sequence with the human genomic sequence (GenBank accession number X74819). Therefore, the primers used in this study are parts of exons. We controlled for the possibility of contaminating genomic DNA by running PCR on RNA extraction specimens with different sets of primers (cTnT-specific and actin-specific). None of the RNA extraction samples showed any presence of contaminating genomic DNA.
The current findings contrast with the recent report by Haller et al. (22 ) , which showed that no evidence of cTnT expression at the mRNA or protein level was demonstrated in truncal skeletal muscle biopsies from five patients with ESRD. One of the limitations in the study by Haller et al. (22 ) was that the anti-cTnT antibody used had reportedly cross-reacted with human skeletal muscle troponin T isoforms. The reduced specificity of the antibody and the low resolution of the immunoblot analysis shown in their report may have limited their conclusions regarding cTnT expression in the skeletal muscle of dialysis patients. Another limitation of the study by Haller et al. (22 ) was that both immunoblot and PCR analysis involved only four biopsies from patients with an increased serum concentration of cTnT. However, our previous study involving 45 biopsy extracts from patients with ESRD screened with specific anti-cTnT antibodies revealed that Ͻ50% will show expression of cTnT isoforms within the range 34 -36 kDa (MAb M11.7) and that Ͻ5% will show expression of 39-kDa cTnT isoforms (MAb M7) (15 ) .
The main findings in the current study were obtained using RT-PCR analysis and oligonucleotide primers specific for the cTnT and cTnI isoforms and the skeletal muscle isoform of troponin T. We showed isoform-specific amplification products in both cardiac and skeletal muscle tissues. We demonstrated the RT-PCR amplification of cTnT, cTnI, and sTnT cDNA sequences from reverse-transcribed muscle RNA. PCR amplification was successful with cardiac muscle-specific primers when used on heart muscle total RNA. No PCR amplification of cardiac primers in reverse-transcribed RNA was found for healthy skeletal muscle samples. Four of seven skeletal muscle specimens from patients with ESRD and two of five skeletal muscle specimens from patients with DMD showed amplification at the expected length (150 bp) for cTnT but not for cTnI. We controlled for the presence of intact sTnT mRNA in each biopsy sample by using primers specific to the slow twitch skeletal muscle sequence. No evidence of sTnT mRNA was found in any of the heart biopsies. However, a 200-bp sTnT amplicon was detected in all skeletal muscle specimens. These results show that all the skeletal muscle specimens, including the ones that did not amplify any cTnT cDNAs in PCR, contained intact cDNAs after reverse transcription and, therefore, contained intact total mRNA.
When we compared our current findings with our previously published results regarding cTnT protein expression using anti-cTnT M11.7 and M7 antibodies (15 ) with RNA expression by RT-PCR analysis in the same biopsy specimens, we found excellent agreement. MAbs M11.7 and M7 are designated as capture and detection antibodies, respectively, in the Roche cTnT second-and third-generation immunoassays. In all specimens from the heart, one major cTnT isoform, with a molecular mass of 39 kDa, and one minor cTnT isoform, with a molecular mass of 34 kDa, were recognized by MAbs M11.7 and M7. These same specimens demonstrated RNA expression of cTnT by a single amplicon product (150 bp). None of the five specimens from healthy skeletal muscle showed either protein or RNA expression of cTnT. Four of seven specimens that demonstrated expression of cTnT protein isoforms (34 -36 kDa) using MAb M11.7 also showed expression of cTnT mRNA by a single amplicon product. The different protein isoforms detected by M11.7 appear to reveal potentially important posttranscriptional (splicing) differences between different ESRD muscle tissues. Both specimens that demonstrated an expression of the 39-kDa cTnT protein isoform using MAb M7 showed expression of cTnT mRNA. Furthermore, as in our previous study (15 ) , we again demonstrated that the anti-cTnT M11.7 and M7 Roche antibodies recognized different epitopes on cTnT isoforms expressed in diseased skeletal muscle. Therefore, even if these cTnT isoforms were released from skeletal muscle into the circulation, they would not be measured by the Roche second-and thirdgeneration cTnT immunoassays.
Our current findings (Fig. 4) also concur with our previous findings (15 ), demonstrating that one major cTnI isoform, with a molecular mass of 25 kDa, was recognized by MAb anti-cTnI JS-1 in heart specimens. This corresponded to mRNA expression of cTnI by a single amplicon product (200 bp, using identical heart specimens). No expression of cTnI protein or mRNA was demonstrated in any of the healthy or diseased skeletal muscle specimens. Furthermore, the 200-bp amplicons found in healthy and diseased skeletal muscle specimens were 100% identical and specific to the human slow twitch skeletal TnT mRNA sequence. The absence of extracardiac cTnI expression in diseased skeletal muscle lends additional support to the hypothesis that the cTnI found in the serum of ESRD or DMD patients originates only from the heart (23 ).
In human cardiac muscle, multiple isoforms of cTnT have been described, which are expressed in fetal, adult, Clinical Chemistry 45, No. 12, 1999 and diseased heart, resulting from alternative splicing of a single cTnT gene (3, 24, 25 ) composed of 17 exons spread over 17 kb. A potential structure of the promoter region has been proposed, and several polymorphisms in both the exonic and intronic regions were identified recently, some of which may act as modulators of the expression of the cTnT gene (26 ) .
However, the precise physiological relevance of the TnT isoforms in human heart currently is poorly understood. Recently, the cTnT gene was located at the CMH2 locus on chromosome 1q32 (17, 25 ) , and mutations in its sequence have been found to be associated with familial hypertropic cardiomyopathy (27, 28 ) . The re-expression of multiple isoforms of cTnT in diseased human skeletal muscle parallels, and probably results from, the expression of these isoforms in differentiating myotubes (29 ) and is consistent with the expression of developmentally expressed fetal isoforms, as described previously for both cTnT (5, 24 ) and creatine kinase isoenzymes (30 ) .
Previous studies have shown that in patients with ESRD, serum concentrations of both cTnT and cTnI are increased without evidence of cardiac ischemia (8 ) . Other studies have shown that serum concentrations of cTnT are significantly lower in patients with fewer cardiac risk factors compared with patients with known coronary artery disease (22 ) . The clinical implications of the current study provide additional evidence consistent with the hypothesis that circulating cTnT or cTnI in either ESRD or DMD patients originates from the heart. We thank Charles Cartwright for excellent technical assistance.
